Upload
valvoltron
View
219
Download
0
Embed Size (px)
Citation preview
8/2/2019 Clinical Case 56
1/21
TAMPARIA, Darwin R.
8/2/2019 Clinical Case 56
2/21
40 year old male patient
- will undergo mitral valve replacement
- DM, hypertension, renal insufficiency
8/2/2019 Clinical Case 56
3/21
8/2/2019 Clinical Case 56
4/21
-is a kind of metabolic disease that is broughtabout by either the insufficient production ofinsulin or the inability of the body to respond
to the insulin formed within the system.
8/2/2019 Clinical Case 56
5/21
-High blood pressure; transitory or sustainedelevation of systemic arterial blood pressure toa level likely to induce cardiovascular damage
or other adverse consequences.
8/2/2019 Clinical Case 56
6/21
-malfunction of the kidneys resulting from anyof a number of causes, including infection,trauma, toxins, hemodynamic abnormalities,
and autoimmune disease, and often resultingin systemic symptoms, especially edema,hypertension, metabolic acidosis, and uremia.
8/2/2019 Clinical Case 56
7/21
-Echocardiogram
-Color-flow Doppler examination
-Cardiac catheterization
-Chest x-ray
-ECG (may show arrhythmias such as atrialfibrillation)
-Chest MRI -CT scan of the chest
8/2/2019 Clinical Case 56
8/21
-surgical treatment of valvular disease. Mitralvalve repair is used to treat regurgitation orstenosis of the mitral valve. It is treated by
removing the diseased valve and implanting anartificial valve (valve replacement).
8/2/2019 Clinical Case 56
9/21
Non-pharmacologic:
Diabetes mellitus
- a number of lifestyle modification
- (DPP) diet and exercise for 30 min/day fivetimes/week
-Maintain normal BMI and engage in regularphysical activity
8/2/2019 Clinical Case 56
10/21
Pharmacologic:
Diabetes mellitus
- Type 1(or insulin dependent) wide range offormulations of Insulin
- Type 2 Sulphonylurea group (e.g.
chlorpropamide , glibenclamide , tolbutamide -biguanide (e.g metformin)
-alpha-glucosidase inhibitors
8/2/2019 Clinical Case 56
11/21
Non-pharmacologic:
Hypertension
- Health promoting lifestyle modifications
- weight loss
- reduction of dietary naCl
- food preference
8/2/2019 Clinical Case 56
12/21
Pharmacologic:
Hypertension
- Diuretics
- Beta Blockers
- Calcium channel blocker
- ARB
- Aldosterone Antagonist
8/2/2019 Clinical Case 56
13/21
General Anesthesia : Local Anesthesia :
Inhalational IV
8/2/2019 Clinical Case 56
14/21
Gaseous Anesthetics:
-Nitrous oxide
-Cyclopropane
Volatile Anesthetics:
A. Non-Halogenated
-Ether
-Chloroform
8/2/2019 Clinical Case 56
15/21
B. Halogenated
-Halothane
-Enflurane
-Isoflurane
-Methoxyflurane
-Sevoflurane
-Desflurane
8/2/2019 Clinical Case 56
16/21
8/2/2019 Clinical Case 56
17/21
-Isoflurane (2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro-ethane) is a halogenated ether usedfor inhalational anesthesia.
-Its name comes from being a structural isomerof enflurane
-produce adequate muscle relaxation
-less nephrotoxic enflurane -less hepatotoxic halothane
8/2/2019 Clinical Case 56
18/21
Brand names:
-Forane
-Terrell
Drug interactions:
May increase the levels/effects of:
-DOPamine
-Epinephrine
-Ephedrine
-NorEpi
8/2/2019 Clinical Case 56
19/21
-absorbtion from alveoli into pulmonarycapillary blood
-distribution in the body
-metabolism -elimination, principally via lungs
8/2/2019 Clinical Case 56
20/21
-Onset of action: 7-10 minutes (odor limitsinhalation rate)
-Duration: emergence time: depends on blood
concentration when discontinued -Metabolism: minimally hepatic
-Excretion: primarily as unmetabolized exhaled
gases
8/2/2019 Clinical Case 56
21/21
-Shivering, nausea, vomiting and ileus havebeen observed in the postoperative period.Resp depression, hypotension, arrhythmias,
malignant hyperthermia.